
Oxygenta (OXYGENTAPH) | Financial Analysis & Statements
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Mar 2025Income Metrics
Revenue
494.7M
Gross Profit
22.4M
4.52%
Operating Income
-14.0M
-2.83%
Net Income
-21.5M
-4.35%
Balance Sheet Metrics
Total Assets
828.0M
Total Liabilities
1.1B
Shareholders Equity
-256.4M
Cash Flow Metrics
Revenue & Profitability Trend
Oxygenta Income Statement From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Revenue | 1.1B | 396.4M | 309.9M | 605.2M | 520.3M |
Cost of Goods Sold | 1.1B | 409.9M | 305.8M | 565.7M | 423.0M |
Gross Profit | 16.7M | -13.5M | 4.1M | 39.6M | 97.3M |
Gross Margin % | 1.5% | -3.4% | 1.3% | 6.5% | 18.7% |
Operating Expenses | |||||
Research & Development | - | - | - | - | - |
Selling, General & Administrative | - | 21.4M | 6.8M | 15.1M | 13.3M |
Other Operating Expenses | 47.1M | 488.0K | 7.9M | 1.8M | 2.9M |
Total Operating Expenses | 47.1M | 21.9M | 14.7M | 16.9M | 16.2M |
Operating Income | -117.3M | -123.7M | -91.5M | -1.2M | 26.5M |
Operating Margin % | -10.7% | -31.2% | -29.5% | -0.2% | 5.1% |
Non-Operating Items | |||||
Interest Income | - | 178.0K | 50.0K | 44.9K | 225.3K |
Interest Expense | 36.1M | 15.8M | 14.7M | 9.1M | 17.8M |
Other Non-Operating Income | - | - | - | - | - |
Pre-tax Income | -143.5M | -138.7M | -113.7M | -4.9M | 31.4M |
Income Tax | -40.5M | -103.9M | 2.0M | 1.2M | 2.1M |
Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 6.8% |
Net Income | -103.0M | -34.8M | -115.7M | -6.1M | 29.3M |
Net Margin % | -9.4% | -8.8% | -37.3% | -1.0% | 5.6% |
Key Metrics | |||||
EBITDA | -68.0M | -96.7M | -71.1M | 14.7M | 39.3M |
EPS (Basic) | - | ₹-1.09 | ₹-8.15 | ₹-0.48 | ₹2.87 |
EPS (Diluted) | - | ₹-1.09 | ₹-8.15 | ₹-0.48 | ₹2.87 |
Basic Shares Outstanding | - | 32039000 | 14201000 | 12743766 | 10201300 |
Diluted Shares Outstanding | - | 32039000 | 14201000 | 12743766 | 10201300 |
Income Statement Trend
Oxygenta Balance Sheet From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 17.0K | 17.0K | 175.0K | 715.1K | 3.7M |
Short-term Investments | 1.2M | 991.0K | 887.0K | 841.7K | 800.0K |
Accounts Receivable | 51.0M | 73.6M | 101.6M | 15.8M | 16.1M |
Inventory | 205.1M | 137.2M | 117.1M | 72.8M | 121.1M |
Other Current Assets | 52.1M | -1.0K | 30.4M | -1 | 18.9M |
Total Current Assets | 309.4M | 241.1M | 250.1M | 95.6M | 159.4M |
Non-Current Assets | |||||
Property, Plant & Equipment | 368.3M | 13.4M | 12.5M | 12.1M | 11.1M |
Goodwill | 0 | - | 0 | - | - |
Intangible Assets | - | - | - | - | - |
Long-term Investments | - | - | - | - | - |
Other Non-Current Assets | - | -1.0K | -1.0K | 1 | - |
Total Non-Current Assets | 518.6M | 390.9M | 292.6M | 216.1M | 179.2M |
Total Assets | 828.0M | 631.9M | 542.6M | 311.8M | 338.6M |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 297.9M | 228.9M | 237.8M | 64.6M | 137.9M |
Short-term Debt | 407.1M | 82.3M | 57.4M | 10.9M | 28.5M |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | 151.1M | 2.8M | 4.4M | 3.2M | 2.9M |
Total Current Liabilities | 858.5M | 337.0M | 329.0M | 80.7M | 175.0M |
Non-Current Liabilities | |||||
Long-term Debt | 215.2M | 490.0M | 622.5M | 510.4M | 450.4M |
Deferred Tax Liabilities | - | 0 | 16.6M | 14.6M | 13.4M |
Other Non-Current Liabilities | - | -1.0K | -1.0K | 0 | 0 |
Total Non-Current Liabilities | 226.0M | 496.2M | 675.7M | 577.4M | 543.9M |
Total Liabilities | 1.1B | 833.1M | 1.0B | 658.1M | 718.8M |
Equity | |||||
Common Stock | 369.8M | 334.8M | 142.0M | 142.0M | 102.0M |
Retained Earnings | - | -638.8M | -604.0M | -488.3M | -482.2M |
Treasury Stock | - | - | - | - | - |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | -256.4M | -201.2M | -462.0M | -346.3M | -380.2M |
Key Metrics | |||||
Total Debt | 622.3M | 572.3M | 679.9M | 521.3M | 478.9M |
Working Capital | -549.0M | -95.9M | -78.9M | 15.0M | -15.5M |
Balance Sheet Composition
Oxygenta Cash Flow Statement From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | -143.5M | -138.7M | -113.7M | -4.9M | 31.4M |
Depreciation & Amortization | - | - | - | - | - |
Stock-Based Compensation | - | - | - | - | - |
Working Capital Changes | 49.7M | 4.4M | -150.0M | 53.9M | -157.6M |
Operating Cash Flow | -89.0M | -118.5M | -248.9M | 58.2M | -108.6M |
Investing Activities | |||||
Capital Expenditures | -112.7M | -41.1M | -96.4M | -49.5M | -67.4M |
Acquisitions | - | - | - | - | - |
Investment Purchases | - | - | - | - | - |
Investment Sales | - | - | - | - | - |
Investing Cash Flow | -112.7M | -41.1M | -96.4M | -49.5M | -67.4M |
Financing Activities | |||||
Share Repurchases | - | - | - | - | - |
Dividends Paid | - | - | - | - | - |
Debt Issuance | - | - | - | - | - |
Debt Repayment | - | - | - | - | - |
Financing Cash Flow | 379.3M | 294.9M | -1.0K | 40.0M | 0 |
Free Cash Flow | -87.9M | -171.6M | -112.8M | -66.3M | -83.6M |
Net Change in Cash | 177.5M | 135.3M | -345.4M | 48.8M | -176.0M |
Cash Flow Trend
Oxygenta Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
444.32
Price to Sales
2.69
Profitability Ratios
Profit Margin
-13.45%
Operating Margin
-50.72%
Return on Equity
40.16%
Return on Assets
-12.44%
Financial Health
Current Ratio
0.36
Debt to Equity
-2.43
Beta
0.56
Per Share Data
EPS (TTM)
₹-2.86
Book Value per Share
₹-7.15
Revenue per Share
₹30.62
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
oxygentaph | 3.0B | 444.32 | - | 40.16% | -13.45% | -2.43 |
Sun Pharmaceutical | 3.9T | 37.74 | 5.43 | 15.08% | 19.29% | 3.26 |
Divi's Laboratories | 1.6T | 70.79 | 10.93 | 14.64% | 23.89% | 0.03 |
Sun Pharma Advanced | 47.8B | -13.92 | -21.95 | 157.88% | -53.22% | -1.24 |
Aarti Drugs | 43.0B | 22.81 | 3.14 | 12.28% | 7.80% | 44.92 |
Sequent Scientific | 44.3B | 153.95 | 6.28 | 2.84% | 1.85% | 62.47 |
Financial data is updated regularly. All figures are in the company's reporting currency.